secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001140361-23-039661
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech Q2 net loss $11.5M ($0.37/sh); cash $60.6M; Phase 3 protocol submitted to FDA
--------------------------------------------------------------------------------

- Net loss of $11.5M ($0.37 per share) vs. $5.8M ($0.20 per share) in Q2 2022.
- R&D expenses rose to $8.0M from $3.8M; G&A rose to $4.7M from $3.3M.
- Cash and equivalents $60.6M; management says sufficient for 12 months.
- Submitted final Phase 3 VERSATILE-003 protocol to FDA to start Q4 2023.
- VERSATILE-002 interim data showed 12-month OS rate of 87% with favorable safety.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036123039661/0001140361-23-039661-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036123039661/brhc20057492_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-039661

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer